Pharmacogenetics in neuropsychiatric diseases: epilepsy as a model.
Individual drug responses are the result of interactions of multiple environmental and genetic factors. Pharmacogenetics studies the influence of genetic variation on interindividual differences in drug efficacy, adverse events and dosing. This article discusses general strategies for candidate gene selection and pharmacogenetic association studies. A summary of the major pharmacogenetic associations reported in neuropsychiatric disease is presented. The example of epilepsy pharmacogenetics will be covered in more detail, including an overview of epilepsy pharmacogenetic candidate genes and results of association studies reported so far. With the advent of large-scale, rigorously designed association studies, it is hoped that genetic factors will be identified that will lead to a targeted, more efficacious and safer treatment, and perhaps to the development of new and more efficacious drugs for neuropsychiatric diseases.
Depondt
C
C
Service de Neurologie, Hôpital Erasme, Université Libre de Bruxelles. cdepondt@ulb.ac.be
D000927:Anticonvulsants / Q000378:metabolism / Q000494:pharmacology; D001923:Brain Chemistry / Q000187:drug effects* / Q000235:genetics; D004351:Drug Resistance / Q000235:genetics; D004827:Epilepsy / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D005786:Gene Expression Regulation / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D008959:Models, Neurological; D009480:Neuropharmacology / Q000379:methods / Q000639:trends; D011619:Psychotropic Drugs / Q000378:metabolism / Q000494:pharmacology
D000927:Anticonvulsants; D011619:Psychotropic Drugs